Sage Journals: Discover world-class research

Abstract

Objective

Calcium spirulan (CaSP) has been shown to prevent host cell penetration by several enveloped viruses, including Herpes simplex virus type 1 (HSV-1), in in vitro experiments. We investigated how CaSP inhibits HSV-1 penetration into human keratinocyte cells by studying the interactions among CaSP, HSV-1, and keratinocytes in vitro.

Methods

After chemical characterization of the CaSP, we conducted two separate experiments. First, we added different HSV-1 viral loads to HaCaT cells that had been incubated with CaSP for 3 h. Second, different viral loads were incubated with CaSP for 3 h and then the resulting mixtures were added to the cells. The incubation period lasted 48 h. The HSV-1 median tissue culture infectious dose (TCID₅₀) was determined by measuring the cytopathic effect (CPE) index and using a colorimetric immunohistochemical (IHC) staining. CaSP degradation and penetration into keratinocytes were determined using an HLPC method developed in house.

Results

CaSP was detected in the supernatant but not in the cells. After pre-incubating the cells with CaSP, a viral load of 4.56 TCID₅₀ was inhibited by concentrations of ≥50 µg/mL of CaSP after 48 h of incubation (CPE ≤2). An activity against the highest HSV-1 TCID₅₀ (114) was observed only with 800 µg/mL of CaSP. Similar effects were observed after 48 h pre-incubation of HSV-1 with CaSP when ≥50 µg/mL of CaSP was added to a viral suspension of 4.56 TCID₅₀. The higher viral load (TCID₅₀ 114) was not inhibited. Sustained inhibition of all HSV-1 titers used (from 0 to 1000 TCID₅₀) was observed only at a CaSP concentration of 800 µg/mL, independent from the pre-incubation method.

Conclusion

CaSP does not enter keratinocytes and seems to interact with both cells and virus as viral inhibition was independent from the preincubation method.

Graphical abstract

This is a visual representation of the abstract.

Keywords

Antiviral activity cold sores herpes labialis keratinocytes mode of action sulfated polysaccharides

Introduction

Herpes simplex virus type 1 (HSV-1) often causes mild, uncomplicated, and often recurrent mucocutaneous infections such as herpes labialis, also known as “cold sores” or “fever blisters”,¹ by entering keratinocytes via a nectin-1-dependent, rapid plasma membrane fusion pathway.² After the initial infection, HSV-1 resides in the neurons of the peripheral nervous system of its host in a latent state, persisting lifelong and often triggering recurrent disease.³ It is estimated that worldwide approx. 3.7 billion people under the age of 50 are latently infected by HSV-1.⁴

HSV-1 can also cause life-threatening diseases,⁵ for which nucleoside analogues such as acyclovir, valaciclovir, penciclovir, and famciclovir are available as oral treatments.^6–9 Herpes labialis management, on the other hand, is mainly symptomatic. Zinc oxide or zinc sulfate creams, as well as antiviral creams containing mainly acyclovir may reduce symptoms duration. Prophylactic treatment with oral or topical antiviral medicines before exposure to sunlight–one of the main triggering factors–may also provide some protection.¹⁰

A water-soluble extract of the cyanobacterium Arthrospira platensis (synonym: Spirulina platensis) has been shown to inhibit HSV-1 replication in HeLa cells in a dose-dependent manner at concentrations of 0.08–50 mg/mL.¹¹ The extract inhibited viral, but not host cell protein synthesis.¹¹ In addition to providing viral protection, A. platensis extracts are known to possess antibacterial properties,¹² to help manage skin health, and to protect the skin barrier.¹³ Calcium spirulan (CaSP), a sulfated, calcium-chelated polysaccharide found in A. platensis extracts,¹⁴ is considered to be one of the most important active pharmacological ingredients in the extracts. Experimental studies, for instance, have suggested that CaSP may reduce tumor invasion and metastasis. CaSP inhibits HSV-1 invasion in the basal membranes of B16-BL6 melanoma cells, Colon 26 M3.1 carcinoma cells, and HT-1080 fibrosarcoma cells. This indicates that inhibition probably occurs by preventing viral adhesion to cell receptors.¹⁵ In vitro, CaSP inhibits blood clot formation and assists in dissolving existing clots by cleaving fibrinogen or fibrin. CaSP acts as a potent enhancer of tissue-type plasminogen activator (t-PA) synthesis and exhibits anticoagulant properties by activating the heparin cofactor II.¹⁶ It has also been shown to have antiviral activity in vitro against several enveloped viruses, including HSV-1, human cytomegalovirus, measles, mumps, influenza, and the human immunodeficiency virus (HIV),^14,17 and topical formulations have been used as a safe treatment option for children with molluscum contagiosum, an infection caused by a poxvirus.¹⁸

The main components of CaSP are 1,3-linked rhamnose and 1,2-linked 3-O-methyl rhamnose (acarbose) units in a ratio of about 5:3,¹⁹ but the molecule also contains ribose, mannose, galactose, xylose, glucose, and galacturonic acid.¹⁴ Replacing calcium with sodium or potassium does not decrease the anti-HSV-1 activity of CaSP, which, is reduced, when calcium is replaced by divalent and trivalent metal cations.²⁰ Depolymerization with hydrogen peroxide also decreases the antiviral potential of CaSP.²⁰ In HaCaT cells (human adult, low calcium, high temperature keratinocytes), CaSP exhibits an anti-HSV-1 activity similar to acyclovir. However, unlike acyclovir, CaSP apparently blocks viral attachment and penetration.²¹

The antiviral activity of a cream containing CaSP has been confirmed in an observational clinical trial on volunteers with recurrent herpes labialis, in which a topical CaSP cream was superior to topical acyclovir in preventing recurrence,²¹ but the mode of action of CaSP against HSV-1 has not been conclusively elucidated. This study aimed at investigating how CaSP inhibits HSV-1 penetration into human keratinocytes by examining the interactions among CaSP, viral particles, and keratinocytes in vitro.

Material and Methods

CaSP Extract, Chemicals, and Reagents

CaSP was provided as a sterile, 1% aqueous solution by Ocean Pharma GmbH (Reinbek, Germany). Acyclovir (ACV), carbamazepine, propranolol, trypan blue solution, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (Taufkirchen, Germany). Heparin and H₂O₂ were provided by Carl Roth (Karlsruhe, Germany), bovine serum albumin (BSA) by PAN Biotech (Aidenbach, Germany), and 3,3′-Diaminobenzidine (DAB) by Roche Diagnostics GmbH (Mannheim, Germany). Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), trypsin-EDTA (0.25%), and Geneticin (G418) were supplied by Gibco (Darmstadt, Germany). Methanol and phosphate-buffered saline (PBS) were obtained from Th. Geyer GmbH & Co. KG (Höxter, Germany), and penicillin-streptomycin, Triton X-100, and sodium dodecyl sulfate (SDS) from Life Technologies/ThermoFisher Diagnostics GmbH (Darmstadt, Germany). Water for injection was purchased from B. Braun AG (Melsungen, Germany) and the XTT assay from Applichem GmbH (Darmstadt, Germany). All analytical-grade solvents were purchased from Merck (Darmstadt, Germany), except for the 99% MS-grade formic acid that was obtained from Biosolve (Valkenswaard, The Netherlands). All other solvents, as well as tris-(hydroxymethyl) aminomethane (Tris) (≥99.9%), NaCl, and sodium deoxycholate, were provided by Carl Roth (Karlsruhe, Germany).

The HaCaT KeratinoSense cell line (RE242, HaCaT cells transfected with an Nrf-2 luciferase reporter plasmid) used for the infection assays was obtained from acCELLerate GmbH (Hamburg, Germany). HSV-1 (2.34 × 10⁶ TCID₅₀ [median tissue culture infectious dose]/mL, catalog number 1806153v, lot number 1555) was provided by Public Health England (National Collection of Pathogenic Viruses [NCPV], Porton Down, Salisbury, England). Rabbit anti-goat IgG H&L (HRP) and anti-HSV-1 goat polyclonal antibody (ab20536) were purchased from Abcam plc (Cambridge, England).

Preparation of CaSP for Analytical and Antiviral Studies

The CaSP solution was freeze-dried in an aluminum bowl with an initial filling height of approximately 0.8 cm. There was no loss in quality or quantity, as confirmed by high-performance liquid chromatography (HPLC) coupled with a refractive index detector (HPLC-RI, VWR Hitachi, Darmstadt, Germany). The samples were frozen at −80 °C prior to freeze drying (FD) in an Alpha 1–4 freeze dryer (Christ, Osterode, Germany) that was run for 12 h at 37 PS. FD samples were stored at −20 °C until further use.

Characterization and Quantitative Measurements of CaSP

We carried out the chemical characterization of CaSP, determined its molecular weight, and checked for impurities present in the sample using an ultra-high-performance liquid chromatography (UPLC) on an Acquity Arc System (Waters Corp., Milford, MA, USA) coupled with a UV/VIS detector (Waters 2998 PDA Detector) and a mass spectrometer (Waters Acquity QDa Detector), using a C18 column (Waters Cortecs C18 2.7 μm, 90 Å, 3.0 × 100 mm,) operated at 40 °C. The injection volume was 5 μL. A H₂O and acetonitrile gradient (0 min: 70% H₂O; 4 min.: 10% H₂O; 9 min: 0% H₂O; 11.5 min: 70% H₂O until 15 min) was used, and the flow velocity was set to 0.5 mL/min. Formic acid (0.1%) was added to both solvents. Optical spectra were recorded within the range 200–800 nm. The mass spectrometer with electrospray ionization was operated in positive mode with a cone voltage of 15 V and a probe temperature of 600 °C at 150–1250 m/z. Mass spectra were evaluated with MassLynx V4.1.

CaSP concentrations were determined using a HPLC-RI Hitachi Primaide System (Hitachi, Krefeld, Germany) equipped with a 1410 UV detector and Chromaster 5450 RI detector module on a Macherey-Nagel VA 300/7.8 Nucleogel Sugar 810 H column (sulfonated polystyrene/divinylbenzene resin, 8-10 μm, 100 Å, 300 mm×7.8 mm, Macherey-Nagel, Düren, Germany) with H₂SO₄ as the solvent at a flow rate of 0.6 mL/min and 35 °C. Spectra were evaluated using the Primaide System Manager HPLC Software provided with the Primaide System.

A calibration curve was established using the peak areas in the range of 0.1–9 mg/mL CaSP (w/v). Cell supernatant and lysate samples were injected directly into the HPLC-RI system, and peak areas were determined to calculate concentrations using the calibration curve.

Quantification of Heparin, Carbamazepine, ACV, and Propranolol

The concentrations of ACV, carbamazepine, and propranolol were measured using a Hitachi Primaide 1430 Diode Array Detector (HPLC-DAD, Hitachi, Krefeld, Germany) on an ACE^® Equivalence 3 System (C18, 3 µm, 110 Å, 150 mm×4.6 mm, VWR Avantor, Darmstadt, Germany). A gradient solvent from 5% to 90% acetonitrile and acidic water (pH 2.2, formic acid) was used at a flow rate of 1.25 mL/min and a temperature of 40 °C. The injection volume was 5 µL. All compounds were quantified at 275 nm. Calibration curves were prepared for each compound and used to determine the concentrations of the compounds in cell lysates and supernatants. For heparin, calibration curves were prepared under the same conditions described for CaSP, but measurements were carried out using an HPLC-RI system.

Recovery of CaSP from Growth media and HaCaT Cells

HaCaT cells (5 × 10⁵ cells/mL), which were pre-adapted to a serum-free medium, were maintained in DMEM supplemented with 10% human platelet lysate (HPL; PL BioScience, Aachen, Germany). The cells were passaged once a week when confluency approached 80%. Cell viability was assessed using a CASY cell counter (OLS Omni Life Science, Bremen, Germany). Once confluency reached approx. 80%, 5, 10, 40, and 100 µg/mL CaSP as well as 100 µg/mL of the controls ACV, carbamazepine, propranolol, and heparin (which is known not to penetrate the cell lumen²²) were added. The cells were then incubated for 1, 2, 3, and 24 h at 37 °C.²³ After incubation, the DMEM in which the cells had been cultivated was collected and vacuum-dried for analysis. Fresh DMEM was also dried and used as a control. The cells attached to the flask were lysed using a radioimmunoprecipitation assay lysis buffer containing Tris-HCl 1 M, Triton X-100, NaCl 5 M, 10% sodium deoxycholate, and 10% SDS (all p.A. grade, Carl Roth, Karlsruhe, Germany).

The concentrations of the test substances were determined at each time point in the supernatant and in the washed lysed cells. If the sum of the concentrations in the supernatant and the lysed cells concentrations did not equal 100%, the difference was considered to be caused by the degradation of the test substance. In all experiments, untreated cells served as a control. Cell viability was measured for all conditions, and all conditions were tested in 3 replicates.

Determination of Cell Viability

Experiments were carried out with HaCaT cells (10⁵ cells/mL, or 2 × 10⁴ cells/well) and cytotoxicity was determined by the XTT assay.²⁴ All measurements were carried out using a Biotek Cytation 5 (Agilent Technologies; Software Gen 5, version 3.14). The maximum concentrations of the compounds used in the experiments were chosen based on viability and cytotoxicity testing results.

Cell viability was also scored by determining the Cytopathic Effect (CPE) index²⁵ using a Zeiss Primovert light microscope, according to the scoring system described in the DIN EN ISO 10993-5_2009-10 documentation.²⁶ CPE scores range from 0 (no cell lysis evident and typical cell morphology) to 4 (complete monolayer disintegration with all the hallmarks of a dying or dead culture). Any other changes in cell morphology, cellular detachment, and signs of viral infection were documented as well.

Minimum Viral Load to be Used in the Experiments

To determine the optimal viral load for the cell entry studies, the cells were incubated with HSV-1 at 7 concentrations ranging from 10⁻³ to 10³ TCID₅₀/mL for 11 days. The experiment was carried out in 8 replicates. Cell viability was scored as described above, and the CPE was determined daily for 11 days.

CaSP Concentrations to be Used in the Infection Studies

The HaCaT cell density was adjusted to 1 × 10⁵ cells/mL. Two hundred µL of the cell suspension were seeded into each well of two 96-well plates, with a separate plate used for each test compound. The plates were pre-incubated without test compounds for about 24 h, washed with DMEM without FBS, and then the test compounds were added. All experiments were carried out at 37 °C under 5% CO₂. 200 µg/mL ACV and growth medium served as controls.

In a first experiment, 100 µL of CaSP, at concentrations ranging from 12.5 to 800 µg/mL, were added to the cells. The plates were incubated for approx. 3 h before 100 µL of three HSV-1 dilutions (0, 4.56, and 114 TCID₅₀/mL) were added to the wells.

In a second experiment, CaSP concentrations ranging from 12.5 to 800 µg/mL were mixed with the three HSV-1 dilutions, incubated for 3 h, and the CaSP/HSV-1 mixture was then added to the cells.

Both experiments were carried out in duplicate. CPE, as well as changes in cell morphology, cellular detachment, and other signs of viral infection, were determined after three days.

HSV-1 Inhibition by CaSP

The cells were seeded at a density of 10⁵ cells/mL, resulting in 2 × 10⁴ cells per well, and incubated for 24 h at 37 °C and 5% CO₂.

In a first experiment the cells were pre-incubated with CaSP, after which different viral loads (serial dilutions ranging from 1000 to 0.017 TCID₅₀/mL) were added to the cells. In a second experiment, the virus was incubated with CaSP for three hours, after which the mixtures of virus and CaSP were added to the cells.

The incubation period for both experiments lasted 48 h. Both experiments were carried out in 8 replicates.

Immunohistochemical Staining

In addition to the CPE index, we evaluated the anti-HSV-1 activity of CaSP using a colorimetric immunohistochemical (IHC) staining with 3,3′-diaminobenzidine (DAB) substrate (Roche Diagnostics GmbH). Briefly, cell monolayers were washed twice with 100 µL of PBS, and 90 µL of cold methanol were added to each well. The plates were then incubated for approx. 15 min. at room temperature (RT). The reaction was blocked by adding 10 µL of 3% H₂O₂ and the plates were then incubated for an additional 15 min. at RT. The monolayer was washed twice more with 100 µL of PBS, after which the anti-HSV-1 primary antibody was added. After 60 min. incubation at RT, the monolayer was washed three times with 100 µL of PBS, the Horseradish peroxidase (HRP)-conjugated secondary antibody was added, and the plates were incubated for 60 min at RT. The monolayer was washed again three times with 100 µL of PBS, 100 µL of the DAB substrate were added to each well, and the plates incubated for 15 min. The substrate was discarded, the cells were washed with 100 µL of distilled water, and the plates dried and analyzed using a Zeiss Primovert light microscope. Readings were taken on days 2 and 3 after inoculation.

Data Analysis

The collected data are non-parametric; therefore, no means or standard deviations were computed. When there are enough repetitions, the medians and the 25^th and 75^th percentiles are computed, otherwise the minimum and maximum values are presented. The results were analyzed only descriptively, as there are not enough data points to allow for formal confirmatory statistical analyses. HSV-1 inhibition is presented graphically as medians ± percentiles (or minimum-maximum) of the concentrations. A CPE of 2 or less was arbitrarily set as the cutoff for HSV-1 inhibiting effects. We present graphical displays of the results, including lowess smoothing curves, resulting from a non-parametric regression technique used to visualize trends in data.²⁷ An analysis of variance (ANOVA) using pretreatment (cells or HSV-1), HSV-1 titer, and CaSP concentrations as covariates, was carried out as an hypothesis-generating analysis with no confirmatory value. All statistical parameters and graphical displays were generated using Stata, version 19.5 (StataCorp., College Station, Texas, USA).

Results

Characterization and Quantitative Measurements of CaSP

UPLC-UV/VIS detected a nonspecific absorption between 200 and 280 nm. HPLC-RI revealed a specific peak (Figure 1A) that was used for calibration. The lowest detection limit was 0.15 µg/mL. Mass spectrometry (Figure 1B) revealed a wide mass variation between 400 and 1200 kDa, with a maximum at 700 kDa.

Figure 1.

A. Chromatogram of a 10% CaSP aqueous solution on an HPLC-RI system using a Nucleogel Sugar 810 H column. H₂SO₄ was used as the solvent. The injection volume was 5 µL, the flow rate 0.6 mL/min, and the temperature 35 °C. HPLC was run for 15 min. B. UPLC-PDA (left) and UPLC-MS (right) spectra of 1% CaSP obtained using a uPLC-DAD-MS system with a C18 column and an H₂O and acetonitrile gradient. Optical spectra were recorded within the 200–800 nm range. The mass spectrometer with electrospray ionization was operated in positive mode with a cone voltage of 15 V and a probe temperature of 600 °C at 150–1250 m/z.

Intracellular and Extracellular Distribution of CaSP

CaSP at a concentration of 100 µg/mL was only detected in the supernatant but not in the HaCaT cells. Similar results were obtained with incubation times of 1, 2, 3, or 24 h (Table 1) and with CaSP concentrations of 5, 10, or 40 µg/mL (data not shown). No penetration into the cells or degradation was observed.

Table 1.

Proportion (as Percentage of the Baseline [0 h]) Inside and Outside HaCaT Cells After Incubation for 1, 2, 3, and 24 h at 37 °C. The Data Refer to an Initial Concentration of 100 µg/mL for all Compounds. Figures are Means (Standard Deviation) of the Percentages of Three Measurements (n = 3). CaSp, Calcium Spirulan; E, Extracellular; I, Intracellular; D, Degradation.

Time (h)		CaSP	Heparin	Acyclovir	Propranolol	Carbamazepine
1	E	100 (5)	100 (2)	86 (2)	42 (1)	4 (2)
	I	0 (0.5)	0 (0.5)	19 (1)	10 (2)	36 (2)
	D	0 (0.5)	0 (0.5)	0 (0.5)	49 (5)	59 (6)
2	E	100 (5)	100 (2)	79 (2)	38 (1)	3 (2)
	I	0 (0.5)	0 (0.5)	21 (1)	10 (2)	34 (2)
	D	0 (0.5)	0 (0.5)	0 (0.5)	51 (5)	58 (6)
3	E	100 (5)	100 (2)	78 (2)	41 (1)	6 (2)
	I	0 (0.5)	0 (0.5)	20 (1)	10 (2)	35 (2)
	D	0 (0.5)	0 (0.5)	0 (0.5)	51 (5)	62 (6)
24	E	100 (4.5)	100 (1)	55 (2)	40 (3)	5 (1)
	I	0 (0.5)	0 (0.5)	45 (3)	10 (1)	35 (4)
	D	0 (0.5)	0 (0.5)	0 (0.5)	50 (5)	60 (3)

As expected, heparin did not penetrate the cell lumina. In contrast, propranolol, ACV, and carbamazepine were detected both intra- and extracellularly (Table 1). Significant degradation was observed only for propranolol and carbamazepine. Cell viability was above 80% in all tested conditions.

Minimum Viral Load to be Used in the Experiments

Visual detection of HIV-1 infection occurred within 3 days after infection already at an HSV-1 titer of 1 TCID₅₀/mL (data not shown). Therefore, we tested the HSV-1 inhibitory activity of CaSP against three viral loads: a control with no viral particles), 4.56 TCID₅₀, and 114 TCID₅₀.

CaSP Concentrations to be Used in the Infection Studies

Pre-Incubation of the HaCaT Cells with CaSP

CaSP inhibited a viral load of 4.56 TCID₅₀ at a concentration ≥50 µg/mL after 48 h of incubation (CPE ≤2). An anti-HSV-1 activity against the highest TCID₅₀ (114) was observed only at a concentration of 800 µg/mL CaSP. After 72 h, anti-HSV-1 activity was observed at concentrations of 400 and 800 µg/mL for 4.56 TCID₅₀. The highest TCID₅₀ level (114) was inhibited only by a concentration of 800 µg/mL CaSP (Figures 2A and 2B). CaSP was not toxic to the cells at any of the concentrations investigated (Figures 2A and 2B, controls). A dose-dependent activity was seen only with an HSV-1 TCID₅₀ of 4.56 at both time points. However, after a 72-h incubation period, only the two highest concentrations (400 and 800 µg/mL) remained active.

Figure 2.

Cytopathic effect (CPE) index as a measure of HSV-1 inactivation by different calcium spirulan (CaSP) concentrations. Higher CPE values indicate lower anti-HSV-1 activity by CaSP. CPE values are the medians of two independent measurements (n = 2). A, 3 h preincubation of HaCaT cells with CaSP; readings taken 48 h after HSV-1 infection. B, 3 h preincubation of cells with CaSP; readings taken 72 h after HSV-1 infection. C, 3 h preincubation of HSV-1 with CaSP; readings taken 48 h after HSV-1 infection. D, 3 h preincubation of HSV-1 with CaSP; readings taken 72 h after HSV-1 infection. Dots, triangles, and diamonds represent the median CPE values. Capped bars show the range of two independent measurements. Lines are lowess smoothing curves. C12, 12.5 µg/mL; C25, 25 µg/mL; C50, 50 µg/mL; C100, 100 µg/mL; C200, 200 µg/mL; C400, 400 µg/mL; C800, 800 µg/mL; Blank, 0 µg/mL; ACV, 200 µg/mL acyclovir. Viral loads: red dash-dot lines and diamonds, control (no viral load); green dashed lines and triangles, TCID₅₀ 4.56; blue solid lines and dots, TCID₅₀ 114.

Pre-Incubation of HSV-1 with CaSP

Similarly, pre-incubating HSV-1 for 3 h with ≥50 µg/mL CaSP led to an inhibition of HSV-1 infection (CPE ≤2) at 48 h when CaSP was added to a viral suspension of 4.56 TCID₅₀. This activity was still present at 72 h with a concentration of >50 µg/mL CaSP. CaSP was not active on the 114 TCID₅₀ at any time (Figure 2C and 2D) and it was not toxic to the cells at any of the investigated concentrations (Figures 2C and 2D, controls). The dose-dependent activity was similar to that observed after preincubating the cells with CaSP.

The results of these two experiments guided us in selecting 200 and 800 µg/mL of CaSP and 48 h incubation time for the HSV-1 inhibition studies.

HSV-1 Inhibition by CaSP

After 48 h of incubation, a CPE ≤2 (ie inhibition of HSV-1 infection) was observed in HaCaT cells with a 12.4 TCID₅₀ HSV-1 titer, when no CaSP was added (Figure 3A). Adding 200 µg/mL CaSP increased cell resistance to HSV-1 penetration to 37.1 TCID₅₀ (Figure 3B). However, sustained inhibition of all HSV-1 titers was only seen at a CaSP concentration of 800 µg/mL (Figure 3C). Pre-treatment of the cells or viral particles with CaSP did not influence the outcomes. In fact, the one-way ANOVA revealed that CaSP concentration (p = 0.0003), and HSV-1 titer (p = 0.0000), were statistically significant factors for HSV-1 inhibition, while the type of pretreatment (p = 0.2511) was not.

Figure 3.

Cytopathic effect (CPE) index versus viral load as a measure of anti-HSV-1 activity by CaSP at concentrations 0 (A), 200 (B), and 800 (C) µg/mL. Higher CPE values denote lower HSV-1 inhibition. Dots and diamonds represent the median values and the capped bars the 25^th and 75^th percentiles of eight independent measurements (n = 8). CPE values displayed are the medians of eight independent measurements. Lines are lowess smoothing curves. Green solid lines and dots, 3 h preincubation of HaCaT cells with CaSP, readings taken 48 h after HSV-1 infection; red dashed lines and diamonds, 3 h preincubation of HSV-1 with CaSP, readings taken 48 h after HSV-1 infection.

We observed a clear reduction in the HSV-1 titer after CaSP treatment as measured by both CPE and IHC measurements, with the concentration of 800 µg/mL CaSP being more active than 200 µg/mL (Table 2).

Table 2.

Reduction of HSV-1 Titers Compared to Control After pre-Incubation of HaCaT Cells or HSV-1 with CaSP. The Reduction Factor has Been Computed Using the Formula R = TCID₅₀(Control)/TCID₅₀(Treatment), Using the Means of Two Measurements (n = 2). CPE, Cytopathic Effect Ivndex; Cells, pre-Incubation of Cells with CaSP; HSV-1, pre-Incubation of HSV-1 with CaSP.

	CaSP Concentration [µg/mL]
	200	800
Pre-incubation of cells with CaSP
CPE	10.23	239.8
IHC	2.63	141.2
Pre-incubation of HSV-1 with CaSP
CPE	6.93	162.2
IHC	1.99	93.3

Discussion

The chemical analysis of the CaSP extract used in this study corroborates previous data suggesting that spirulan is a polysaccharide with chains of various lengths.²⁸ Mass spectrometry revealed significant variation in the CaSP mass, ranging from 400 to 1200 kDa, with a peak at 700 kDa. Molecules of this size are unlikely to penetrate the cell membrane, as shown in a previous study on a different model of transmembrane transport, in which only molecules with a maximum size of approx. 150 kDa could diffuse passively through the cell membrane.²⁹

CaSP reduces HSV-1-induced cytopathic effects on HaCaT cells, without affecting cell viability. Pretreating human keratinocytes with CaSP or preincubating HSV-1 with CaSP inhibits HSV-1 penetration. These results align with previous observations that the antiviral activity of CaSP depends on the timing of addition during infection: reduced activity is observed when CaSP is added post-infection, while optimal antiviral effects are seen when it is added during infection or shortly thereafter.²⁰

The efficacy demonstrated by pre-incubating cells or HSV-1 particles with CaSP indicates that CaSP is effective at preventing cell infection. HSV-1 penetration in the cells was inhibited during the first 48 h, indicating that CaSP primarily hinders virus entry, as suggested by previous studies.³⁰ We observed a statistically significant, dose-dependent activity of CaSP regardless of the pre-incubation method used (p = 0.2511). A dose-dependent relationship was observed at a low (4.56 TCID₅₀) HSV-1 titer, whereas only 400 and 800 µg/ml CaSP were active against the high (114) TCID₅₀ titer.

At a concentration of 800 µg/mL, the efficacy of CaSP against a viral TICD₅₀ of approx. 5 is comparable to that of 200 µg/mL of acyclovir. CaSP's antiviral activity decreases over time, a trait also observed with acyclovir. Acyclovir exhibits significant antiviral activity within the first 48 h, but its effectiveness diminishes over time, especially compared to drugs with a longer intracellular half-life.^31,32

However, while the virustatic action of acyclovir has been extensively studied (eg,^25,29) the mode of action of CaSP and other sulfated polysaccharides remains unclear. In our cell penetration study, we used heparin as a negative control, because it is a highly sulfated polysaccharide with a strong negative charge due to numerous sulfate groups. Similar to CaSP, heparin does not penetrate cells,³³ yet it exhibits significant antiviral activity against several viruses, most notably SARS-CoV-2 (COVID-19).³⁴ While heparin is primarily known as an anticoagulant, it is also considered a pleiotropic drug with anti-inflammatory and antiviral properties.³⁵ As an antiviral agent, heparin binds directly to the viral surface proteins, probably acting as a coating agent.³⁶ Our results suggest that CaSP, also a sulfated polysaccharide, may act similarly to heparin by inhibiting viral attachment to cell surfaces.³⁷ The antiviral efficacy of heparin against HSV-1 is directly linked to its sulfation moiety³⁸ a feature reported, at least indirectly, for CaSP.²⁰ Mader et al²¹ showed that CaSP blocks viral attachment and penetration into host cells. CaSP has also been shown to inhibit cell penetration of a wide variety of enveloped viruses,¹⁷ including HSV-1, human cytomegalovirus, measles, influenza, and HIV-1, with half-maximal effective concentrations (EC₅₀) values in the 0.92–23 mg/mL range.³⁹ As with other polysaccharides, it is unlikely that CaSP acts via specific receptor binding activities.

This study has some limitations. First, the penetration study was not carried out for a long period of time. Four time points up to 24 h were studied, which may not reflect long-term cellular interactions or degradation. Additionally, the CaSP/HSV-1 interaction has not been studied using molecular assays. Binding assays and ligand-receptor interaction studies similar to those carried out with other compounds,^40,41 would help elucidate the mode of action of CaSP further. Finally, this study design does not allow drawing conclusions about the clinical significance of the observed interactions between CaSP and HSV-1. However, the results of Mader et al²¹ confirm the efficacy of CaSP in the symptomatic treatment of herpes labialis.

Conclusions

Marine sulfate polysaccharides derived from seaweed and other marine organisms have garnered interest as potential antiviral agents. Their natural abundance, minimal toxicity, and potential as a renewable resource make them important assets that open the doors to safe, innovative antiviral therapies. Our study demonstrates that CaSP does not enter keratinocytes, thus not interfering with the cell metabolic activities, and it provides further evidence of a non-toxic interaction between CaSP and human keratinocytes, which prevents HSV-1 infection.

Taken together, our results support the use of CaSP in the topical prophylaxis and treatment of recurrent HSV-1 infections.⁴²

Footnotes

Abbreviations

Acknowledgements

Orlando and Liliane Petrini (Breganzona, Switzerland) critically reviewed the manuscript.

ORCID iDs

Nils Günnewich

Antje Labes

Ethical Approval

Ethical Approval is not applicable for this article.

Statement of Human and Animal Rights

This article does not contain any studies with human or animal subjects.

Statement of Informed Consent

There are no human subjects in this article and informed consent is not applicable.

Author Contributions

CZ had the idea for this study and supervised its implementation together with NG. AL and MJM planned and supervised the scientific aspects of the study. NA, DE, LN-P, SP, and MJ performed and analyzed the experiments with keratinocytes. AL, NA, SP, NG, and CZ prepared the manuscript and reviewed the results. All authors were involved in the preparation and review of the manuscript.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Cesra Arzneimittel GmbH & Co. KG, Flugstrasse 11, 76532 Baden-Baden, Germany.

Declaration of Conflicting Interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian Zimmermann and Nils Günnewich are employees of Cesra Arzneimittel GmbH. Deniz Elyorgun, Nuril Azizah and Antje Labes received a project-specific grant. Silvia Pezer, Larissa Nkenmei-Pietsch and Marina Jorge Miranda work for Tentamus Pharma & Med Deutschland GmbH, a contract research organization that specializes in preclinical research.

Data Availability Statement

Data from the study are available from the corresponding author upon justified request.

References

Pica

Volpi

. Public awareness and knowledge of herpes labialis. J Med Virol. 2012;84(1):132-137. doi:10.1002/jmv.22233

Sayers

Elliott

. Herpes simplex virus 1 enters human keratinocytes by a Nectin-1-dependent, rapid plasma membrane fusion pathway that functions at low temperature. J Virol. 2016;90(22):10379-10389. doi:10.1128/JVI.01582-16

Kropp

Sun

Viejo-Borbolla

. Colonization of peripheral ganglia by herpes simplex virus type 1 and 2. Curr Opin Virol. 2023;60:101333. doi:10.1016/j.coviro.2023.101333

Herpes simplex virus. World Health Organization. December 11, 2024. Accessed May 7, 2025. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus.

Whitley

Roizman

. Herpes simplex virus infections. Lancet Lond Engl. 2001;357(9267):1513-1518. doi:10.1016/S0140-6736(00)04638-9

Chi

Wang

Delamere

Wojnarowska

Peters

Kanjirath

. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev. 2016;2016(8):CD010095. doi:10.1002/14651858.CD010095.pub2

Gopinath

Koe

Maharajan

Panda

. A comprehensive overview of epidemiology, pathogenesis and the management of herpes labialis. Viruses. 2023;15(1):225. doi:10.3390/v15010225

Leung

AKC

Barankin

. Herpes Labialis: an update. Recent Pat Inflamm Allergy Drug Discov. 2017;11(2):107-113. doi:10.2174/1872213X11666171003151717

Schuster

Harder

Schlichtenbrede

Jarczok

Tesarz

. Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Cochrane Database Syst Rev. 2016;2016(11):CD011503. doi:10.1002/14651858.CD011503.pub2

10.

Opstelten

Neven

Eekhof

. Treatment and prevention of herpes labialis. Can Fam Physician Med Fam Can. 2008;54(12):1683-1687.

11.

Hayashi

Morita

Kojima

. An extract from Spirulina platensis is a selective inhibitor of herpes simplex virus type 1 penetration into HeLa cells. Phytother Res. 1993;7(1):76-80. doi:10.1002/ptr.2650070118

12.

Pianta

Günnewich

Zimmermann

, et al. In vitro antibacterial and antifungal activity of an Arthrospira platensis (syn. Spirulina platensis) extract. Nat Prod Commun. 2025;20(1):1-6. doi:10.1177/1934578X251314702

13.

Reich

Trettel

Reich

JLK

, et al. Effects of a gel containing the defined microalgae extract Spiralin® on the skin microbiome and clinical activity in atopic dermatitis: a double-blind, intraindividual vehicle-controlled proof-of-concept study. Skin Pharmacol Physiol. 2025;38(5-6):1-5. doi:10.1159/000547835

14.

Hayashi

Kojima

. A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Res Hum Retroviruses. 1996;12(15):1463-1471. doi:10.1089/aid.1996.12.1463

15.

Mishima

Murata

Toyoshima

, et al. Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis. Clin Exp Metastasis. 1998;16(6):541-550. doi:10.1023/a:1006594318633

16.

Hayakawa

Hayashi

Ozawa

Niiya

Sakuragawa

. Calcium spirulan as an inducer of tissue-type plasminogen activator in human fetal lung fibroblasts. Biochim Biophys Acta. 1997;1355(3):241-247. doi:10.1016/s0167-4889(96)00137-1

17.

Reis

Cadamuro

Cabral

da Silva I

Rodríguez-Lázaro

Fongaro

. Broad spectrum algae compounds against viruses. Front Microbiol. 2022;12:809296. doi:10.3389/fmicb.2021.809296

18.

Jungclaus

Mascarenhas

Tellechea

Reich

JLK

Reich

. Open-label observational study of a topical formulation of calcium spirulan contained in a defined extract of the microalga Spirulina platensis in the treatment of children with molluscum contagiosum. Dermatol Res Pract. 2023;2023(1):1. doi: 10.1155/2023/8871299

19.

Lee

Hayashi

Sankawa

. Structural analysis of calcium spirulan (Ca-SP)-derived oligosaccharides using electrospray ionization mass spectrometry. J Nat Prod. 2000;63(1):136-138. doi:10.1021/np990348b

20.

Lee

Srisomporn

Hayashi

Tanaka

Sankawa

Hayashi

. Effects of structural modification of calcium spirulan, a sulfated polysaccharide from Spirulina platensis, on antiviral activity. Chem Pharm Bull (Tokyo). 2001;49(1):108-110. doi:10.1248/cpb.49.108

21.

Mader

Gallo

Schommartz

, et al. Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis. J Allergy Clin Immunol. 2016;137(1):197-203. e3. doi:10.1016/j.jaci.2015.07.027

22.

Lundberg

Wikström

Johansson

. Cell surface adherence and endocytosis of protein transduction domains. Mol Ther. 2003;8(1):143-150. doi:10.1016/s1525-0016(03)00135-7

23.

Kratz

Teixeira

Koester

Simões

CMO

. An HPLC-UV method for the measurement of permeability of marker drugs in the Caco-2 cell assay. Braz J Med Biol Res [Rev Bras Pesqui Medicas E Biol]. 2011;44(6):531-537. doi:10.1590/s0100-879 ( 2011007500060

24.

Brosin

Wolf

Mattheus

Heise

. Use of XTT-assay to assess the cytotoxicity of different surfactants and metal salts in human keratinocytes (HaCaT). A feasible method for in vitro testing of skin irritants. Acta Derm Venereol. 1997;77(1):26-28. doi:10.2340/0001555577026028

25.

Suchman

Blair

. Cytopathic effects of viruses protocols. Amer Soc Microbiol. June 2, 2012. Accessed May 7, 2025. https://web.archive.org/web/20120602171845/http:/microbelibrary.org/component/resource/laboratory-test/2875-cytopathic-effects-of-viruses-protocols.

26.

Technical Committee ISO/TC 194. ISO 10993-5 Biological evaluation of medical devices. Part 5: Tests for in vitro cytotoxicity. Published online 2009.

27.

Cleveland

. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74(368):829-836. doi:10.1080/01621459.1979.10481038

28.

Rajasekar

Palanisamy

Anjali

, et al. Isolation and structural characterization of sulfated polysaccharide from Spirulina platensis and its bioactive potential: in vitro antioxidant, antibacterial activity and Zebrafish growth and reproductive performance. Int J Biol Macromol. 2019;141:809-821. doi:10.1016/j.ijbiomac.2019.09.024

29.

Pellegrin

Fernandez

Lamb

NJC

Bennes

. Macromolecular uptake is a spontaneous event during mitosis in cultured fibroblasts: implications for vector-dependent plasmid transfection. Mol Biol Cell. 2002;13(2):570-578. doi:10.1091/mbc.01-06-0280

30.

Rechter

König

Auerochs

, et al. Antiviral activity of Arthrospira-derived spirulan-like substances. Antiviral Res. 2006;72(3):197-206. doi:10.1016/j.antiviral.2006.06.004

31.

Sawtell

Thompson

Stanberry

Bernstein

. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis. 2001;184(8):964-971. doi:10.1086/323551

32.

Sutton

Boyd

. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob Agents Chemother. 1993;37(4):642-645. doi:10.1128/AAC.37.4.642

33.

Betz

Nowbakht

Imboden

Imanidis

. Heparin penetration into and permeation through human skin from aqueous and liposomal formulations in vitro. Int J Pharm. 2001;228(1):147-159. doi:10.1016/S0378-5173(01)00832-8

34.

Conzelmann

Müller

Perkhofer

, et al. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. Clin Med Lond Engl. 2020;20(6):e218-e221. doi:10.7861/clinmed.2020-0351

35.

Vitiello

Ferrara

. Low molecular weight heparin, anti-inflammatory/immunoregulatory and antiviral effects, a short update. Cardiovasc Drugs Ther. 2023;37(2):277-281. doi:10.1007/s10557-021-07251-6

36.

Helgers

Vlaming

Kaptein

Eder

Duitman

Geijtenbeek

TBH

. Heparin provides antiviral activity against Rhinovirus-16 via an heparan sulfate proteoglycan-independent mechanism. Int J Mol Sci. 2025;26(21):10393. doi:10.3390/ijms262110393

37.

Hernández-Corona

Nieves

Meckes

Chamorro

Barron

. Antiviral activity of Spirulina maxima against herpes simplex virus type 2. Antiviral Res. 2002;56(3):279-285. doi:10.1016/s0166-3542(02)00132-8

38.

Copeland

Balasubramaniam

Tiwari

, et al. Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry. 2008;47(21):5774-5783. doi:10.1021/bi800205t

39.

Wei

Wang

, et al. Advances in research on antiviral activities of sulfated polysaccharides from seaweeds. Pharm Basel. 2022;15(5):581. doi:10.3390/ph15050581

40.

Bergefall

Trybala

Johansson

, et al. Chondroitin sulfate characterized by the E-disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells. J Biol Chem. 2005;280(37):32193-32199. doi:10.1074/jbc.M503645200

41.

Gescher

Hensel

Hafezi

Derksen

Kühn

. Oligomeric proanthocyanidins from Rumex acetosa L. Inhibit the attachment of herpes simplex virus type-1. Antiviral Res. 2011;89(1):9-18. doi:10.1016/j.antiviral.2010.10.007

42.

Furman

de Miranda

St Clair

Elion

. Metabolism of Acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother. 1981;20(4):518-524. doi:10.1128/AAC.20.4.518

Calcium Spirulan from Arthrospira platensis (Spirulina) Prevents Herpes simplex Virus Type I Cell Entry in vitro

Abstract

Objective

Methods

Results

Conclusion

Keywords

Introduction

Material and Methods

CaSP Extract, Chemicals, and Reagents

Preparation of CaSP for Analytical and Antiviral Studies

Characterization and Quantitative Measurements of CaSP

Quantification of Heparin, Carbamazepine, ACV, and Propranolol

Recovery of CaSP from Growth media and HaCaT Cells

Determination of Cell Viability

Minimum Viral Load to be Used in the Experiments

CaSP Concentrations to be Used in the Infection Studies

HSV-1 Inhibition by CaSP

Immunohistochemical Staining

Data Analysis

Results

Characterization and Quantitative Measurements of CaSP

Intracellular and Extracellular Distribution of CaSP

Minimum Viral Load to be Used in the Experiments

CaSP Concentrations to be Used in the Infection Studies

Pre-Incubation of the HaCaT Cells with CaSP

Pre-Incubation of HSV-1 with CaSP

HSV-1 Inhibition by CaSP

Discussion

Conclusions

Footnotes

Abbreviations

Acknowledgements

ORCID iDs

Ethical Approval

Statement of Human and Animal Rights

Statement of Informed Consent

Author Contributions

Funding

Declaration of Conflicting Interests

Data Availability Statement

References